Insider · CIK 0001397266
Fust Matthew K
director
Files at NMRA (Neumora Therapeutics, Inc.). First filing Oct 18, 2024, latest Oct 18, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $371k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 23Weak | sell 210b5-1 | NMRA Neumora Therapeutics, Inc. | $371k | 21,788 | -78% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -85,586 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,802 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,571 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +85,586 | - | - | 85,586 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +27,802 | - | - | 27,802 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,571 | - | - | 28,571 | Feb 18, 2025 |
| Oct 17, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,783 | $8.32 | $31k | 23,883 | Oct 18, 2024 |
| Oct 17, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +1,800 | $8.79 | $16k | 25,683 | Oct 18, 2024 |
| Oct 17, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +2,156 | $2.52 | $5,433 | 27,839 | Oct 18, 2024 |
| Oct 17, 2024 | NMRA Neumora Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,739 | $17.01 | $132k | 20,100 | Oct 18, 2024 |
| Oct 18, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,205 | $8.79 | $55k | 26,305 | Oct 18, 2024 |
| Oct 18, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +7,844 | $2.52 | $20k | 34,149 | Oct 18, 2024 |
| Oct 18, 2024 | NMRA Neumora Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -14,049 | $17.03 | $239k | 20,100 | Oct 18, 2024 |
| Oct 17, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,783 | $0.00 | $0 | 0 | Oct 18, 2024 |
| Oct 17, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,800 | $0.00 | $0 | 6,205 | Oct 18, 2024 |
| Oct 17, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,156 | $0.00 | $0 | 93,430 | Oct 18, 2024 |
| Oct 18, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,205 | $0.00 | $0 | 0 | Oct 18, 2024 |
| Oct 18, 2024 | NMRA Neumora Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,844 | $0.00 | $0 | 85,586 | Oct 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.